DE60315886D1 - Substituierte pyrazin- oder pyridin-derivate als glukokinase-aktivatoren - Google Patents
Substituierte pyrazin- oder pyridin-derivate als glukokinase-aktivatorenInfo
- Publication number
- DE60315886D1 DE60315886D1 DE60315886T DE60315886T DE60315886D1 DE 60315886 D1 DE60315886 D1 DE 60315886D1 DE 60315886 T DE60315886 T DE 60315886T DE 60315886 T DE60315886 T DE 60315886T DE 60315886 D1 DE60315886 D1 DE 60315886D1
- Authority
- DE
- Germany
- Prior art keywords
- pyridine derivatives
- substituted pyrazin
- glucocinase
- activators
- glucocinase activators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical class C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43280602P | 2002-12-12 | 2002-12-12 | |
US432806P | 2002-12-12 | ||
US52453103P | 2003-11-24 | 2003-11-24 | |
US524531P | 2003-11-24 | ||
PCT/EP2003/014055 WO2004052869A1 (en) | 2002-12-12 | 2003-12-11 | 5-substituted-pyrazine or pyridine glucokinase activators |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60315886D1 true DE60315886D1 (de) | 2007-10-04 |
DE60315886T2 DE60315886T2 (de) | 2008-05-15 |
Family
ID=32511672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60315886T Expired - Lifetime DE60315886T2 (de) | 2002-12-12 | 2003-12-11 | Substituierte pyrazin- oder pyridin-derivate als glukokinase-aktivatoren |
Country Status (27)
Country | Link |
---|---|
US (1) | US7132425B2 (de) |
EP (1) | EP1572670B1 (de) |
JP (1) | JP4490285B2 (de) |
KR (1) | KR100743890B1 (de) |
AR (1) | AR046244A1 (de) |
AT (1) | ATE370936T1 (de) |
AU (1) | AU2003292229B2 (de) |
BR (1) | BR0317268A (de) |
CA (1) | CA2506441C (de) |
CY (1) | CY1106989T1 (de) |
DE (1) | DE60315886T2 (de) |
DK (1) | DK1572670T3 (de) |
ES (1) | ES2291697T3 (de) |
HK (1) | HK1085481A1 (de) |
HR (1) | HRP20050512A2 (de) |
MX (1) | MXPA05006250A (de) |
MY (1) | MY141521A (de) |
NO (1) | NO330139B1 (de) |
NZ (1) | NZ540298A (de) |
PA (1) | PA8592001A1 (de) |
PE (1) | PE20040801A1 (de) |
PL (1) | PL377551A1 (de) |
PT (1) | PT1572670E (de) |
RU (1) | RU2310648C2 (de) |
TW (1) | TW200426139A (de) |
UY (1) | UY28121A1 (de) |
WO (1) | WO2004052869A1 (de) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933236B2 (en) | 2012-05-22 | 2015-01-13 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
JP2006509774A (ja) | 2002-10-03 | 2006-03-23 | ノバルティス アクチエンゲゼルシャフト | 2型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換(チアゾール−2−イル)−アミドまたはスルホンアミド |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
EP1594863A1 (de) * | 2003-02-11 | 2005-11-16 | Prosidion Limited | Tricyclo-substituierte amid glucokinase-aktivatoren |
PT1735322E (pt) | 2004-04-02 | 2012-01-12 | Novartis Ag | Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2 |
WO2005095417A1 (en) | 2004-04-02 | 2005-10-13 | Novartis Ag | Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions |
KR101066882B1 (ko) * | 2004-12-03 | 2011-09-26 | 트랜스테크 파르마, 인크. | 헤테로방향족 글루코키나제 활성화제 |
US20090281142A1 (en) * | 2005-08-31 | 2009-11-12 | Astellas Pharma Inc. | Thiazole derivative |
JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
KR20080048504A (ko) | 2005-09-29 | 2008-06-02 | 사노피-아벤티스 | 페닐- 및 피리디닐-1,2,4-옥사디아졸론 유도체, 이의제조방법 및 약제로서의 이의 용도 |
GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
EP1948614A2 (de) * | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinaseaktivatoren |
EP2001875A2 (de) | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Glucokinase-aktivatoren |
US8211925B2 (en) * | 2006-04-28 | 2012-07-03 | Transtech Pharma, Inc. | Benzamide glucokinase activators |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
WO2007143434A2 (en) | 2006-05-31 | 2007-12-13 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents |
EP2261216A3 (de) | 2006-07-24 | 2011-12-14 | F. Hoffmann-La Roche AG | Pyrazole als Glucokinase Aktivierer |
FR2903985B1 (fr) | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
FR2904316B1 (fr) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
US7902248B2 (en) * | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
WO2008074694A1 (en) * | 2006-12-20 | 2008-06-26 | F. Hoffmann-La Roche Ag | Crystallization of glucokinase activators |
EP2091947A2 (de) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinaseaktivatoren |
TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
FR2910473B1 (fr) | 2006-12-26 | 2009-02-13 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. |
US8314247B2 (en) * | 2007-01-10 | 2012-11-20 | Mitsubishi Tanabe Pharma Corporation | Hydrazone derivative |
WO2008098244A1 (en) | 2007-02-09 | 2008-08-14 | Metabasis Therapeutics, Inc. | Novel antagonists of the glucagon receptor |
JP5248477B2 (ja) * | 2007-03-07 | 2013-07-31 | 杏林製薬株式会社 | グルコキナーゼ活性化物質 |
US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
WO2008122511A2 (en) | 2007-04-04 | 2008-10-16 | F. Hoffmann-La Roche Ag | Process for preparing 2-amino- [5-(1(s), 2-dihydroxyethyl) or - (ks) -hydroxy-2-haloethyl) ] -pyrazine derivatives by enzymatic reduction of the corresponding ketones |
JP2010524861A (ja) * | 2007-04-20 | 2010-07-22 | メルク フロスト カナダ リミテツド | ステアロイル−補酵素aデルタ−9デサチュラーゼの阻害剤としての新規な複素環式芳香族化合物 |
WO2009022179A2 (en) * | 2007-08-14 | 2009-02-19 | Astrazeneca Ab | Glucokinase activators in the treatment of osteoarthritis |
ES2446932T3 (es) * | 2007-10-08 | 2014-03-10 | Advinus Therapeutics Private Limited | Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina |
CN101918363B (zh) | 2008-01-18 | 2012-09-05 | 安斯泰来制药株式会社 | 苯乙酰胺衍生物 |
US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
HUE025224T2 (en) | 2008-04-28 | 2016-02-29 | Kyorin Seiyaku Kk | Ciklopentilakrilsav amide derivatives |
CA2966273C (en) | 2008-08-13 | 2019-08-27 | Metabasis Therapeutics, Inc. | Glucagon antagonists |
UA104742C2 (uk) * | 2008-12-19 | 2014-03-11 | Эли Лилли Энд Компани | Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази |
US20110021570A1 (en) * | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
US20110040091A1 (en) | 2009-08-13 | 2011-02-17 | Stephan Bachmann | Process for the preparation of (r)-2-phenyl propionic acid derivatives |
US20110054174A1 (en) | 2009-08-28 | 2011-03-03 | Stephan Bachmann | Process for the preparation of a glucokinase activator compound |
CA2779073C (en) | 2009-10-30 | 2017-10-24 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
US8222416B2 (en) | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
ES2893699T3 (es) | 2010-03-31 | 2022-02-09 | Scripps Research Inst | Reprogramación de células |
ES2559209T3 (es) | 2010-04-14 | 2016-02-11 | Bristol-Myers Squibb Company | Nuevos activadores de la glucocinasa y métodos de uso de los mismos |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
NZ610225A (en) * | 2010-11-16 | 2015-08-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
US8470866B2 (en) | 2011-05-03 | 2013-06-25 | Hoffmann-La Roche Inc. | Isoindolinone derivatives |
MX2014005304A (es) | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
CA2898679A1 (en) | 2013-03-14 | 2014-09-25 | Xenon Pharmaceuticals Inc. | Substituted triazolopyridines and methods of use thereof |
EP2970156B1 (de) | 2013-03-15 | 2018-07-25 | Genentech, Inc. | Substituierte benzoxazole und verfahren zur verwendung davon |
MX368243B (es) | 2013-08-23 | 2019-09-25 | Parion Sciences Inc | Agentes mucolíticos de ditiol. |
US9403779B2 (en) | 2013-10-08 | 2016-08-02 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors |
US9278963B2 (en) | 2013-10-10 | 2016-03-08 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
EP3060217B1 (de) | 2013-10-24 | 2022-06-08 | Mayo Foundation for Medical Education and Research | Behandlung polyzystischer erkrankungen mit einem hdac6-hemmer |
EP3074377B1 (de) | 2013-11-27 | 2018-10-17 | Genentech, Inc. | Substituierte benzamide und verfahren zur verwendung davon |
EP2878339A1 (de) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3-Antagonisten |
CR20160308A (es) | 2013-12-03 | 2016-11-08 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
US10076504B2 (en) | 2014-06-12 | 2018-09-18 | Ligand Pharmaceuticals, Inc. | Glucagon antagonists |
JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック, インコーポレイテッド | 治療用化合物及びその使用方法 |
AU2015288060A1 (en) | 2014-07-07 | 2017-02-09 | Acetylon Pharmaceuticals, Inc. | Treatment of leukemia with histone deacetylase inhibitors |
AU2015308438B2 (en) | 2014-08-27 | 2018-12-13 | Prexton Therapeutics Sa | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
CN107438436A (zh) | 2014-12-05 | 2017-12-05 | 摩德纳和雷焦艾米利亚大学 | 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合 |
CN107614480B (zh) * | 2015-01-30 | 2020-09-15 | 帕里昂科学公司 | 新型单硫醇粘液溶解剂 |
CA2984424A1 (en) | 2015-04-30 | 2016-11-03 | Parion Sciences, Inc. | Novel prodrugs of dithiol mucolytic agents |
NZ737536A (en) | 2015-05-22 | 2019-04-26 | Genentech Inc | Substituted benzamides and methods of use thereof |
US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
WO2017032874A1 (en) | 2015-08-27 | 2017-03-02 | Prexton Therapeutics Sa | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
KR20180067561A (ko) | 2015-09-28 | 2018-06-20 | 제넨테크, 인크. | 치료 화합물 및 그의 사용 방법 |
CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
CN109071426A (zh) | 2016-03-30 | 2018-12-21 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
US11813261B2 (en) | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
MA45714A (fr) | 2016-07-22 | 2019-05-29 | Bristol Myers Squibb Co | Activateurs de glucokinase et leurs procédés d'utilisation |
MA46546A (fr) | 2016-10-17 | 2021-05-05 | Genentech Inc | Composés thérapeutiques et leurs procédés d'utilisation |
EP3601273B1 (de) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamid-derivate als natriumkanalinhibitoren |
US11028075B2 (en) | 2018-02-26 | 2021-06-08 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
JP2021519788A (ja) | 2018-03-30 | 2021-08-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE249241C (de) | 1910-05-01 | 1912-07-13 | ||
US3431301A (en) | 1966-03-24 | 1969-03-04 | Hoffmann La Roche | Process for producing methylhydrazine derivatives |
US3776917A (en) | 1972-06-05 | 1973-12-04 | Schering Corp | 2-amino-6-phenalkyl-aminopyridines and derivatives thereof |
ES419319A1 (es) | 1973-10-04 | 1976-03-01 | Gallardo Antonio Sa | Un procedimiento para la obtencion de derivados de acidos 3-benzoilfenilalcanoicos. |
GB8909574D0 (en) | 1989-04-26 | 1989-06-14 | Ici Plc | Chemical process |
US5169951A (en) | 1990-04-23 | 1992-12-08 | Ciba-Geigy Corporation | Process for preparing nematicidal compositions |
EP0566138B1 (de) | 1992-04-17 | 1998-11-18 | Hodogaya Chemical Co., Ltd. | Amino-Thiazolderivate und ihre Anwendung als Fungizide |
US5556859A (en) | 1994-12-22 | 1996-09-17 | Dowelanco | N-(4-pyrimidinyl)amide pesticides |
GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
RU2242469C2 (ru) | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Активаторы глюкокиназы |
SI1169312T1 (en) * | 1999-03-29 | 2005-02-28 | F. Hoffmann-La Roche Ag | Glucokinase activators |
US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
WO2001083478A2 (en) * | 2000-05-03 | 2001-11-08 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
AU7049401A (en) | 2000-05-03 | 2001-11-12 | Hoffmann La Roche | Alkynyl phenyl heteroaromatic glucokinase activators |
US6489485B2 (en) | 2000-05-08 | 2002-12-03 | Hoffmann-La Roche Inc. | Para-amine substituted phenylamide glucokinase activators |
CN1245394C (zh) | 2000-05-08 | 2006-03-15 | 霍夫曼-拉罗奇有限公司 | 作为葡糖激酶激活剂的取代的苯乙酰胺及其用途 |
JP4138478B2 (ja) | 2000-07-20 | 2008-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | アルファ−アシル及びアルファ−ヘテロ原子置換ベンゼンアセトアミドのグルコキナーゼアクチベーター |
US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
BR0115999A (pt) | 2000-12-06 | 2003-09-30 | Hoffmann La Roche | Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto |
US6433188B1 (en) | 2000-12-06 | 2002-08-13 | Wendy Lea Corbett | Fused heteroaromatic glucokinase activators |
-
2003
- 2003-12-10 US US10/732,838 patent/US7132425B2/en not_active Expired - Fee Related
- 2003-12-10 PE PE2003001259A patent/PE20040801A1/es not_active Application Discontinuation
- 2003-12-10 MY MYPI20034740A patent/MY141521A/en unknown
- 2003-12-11 RU RU2005121667/04A patent/RU2310648C2/ru not_active IP Right Cessation
- 2003-12-11 MX MXPA05006250A patent/MXPA05006250A/es active IP Right Grant
- 2003-12-11 DE DE60315886T patent/DE60315886T2/de not_active Expired - Lifetime
- 2003-12-11 NZ NZ540298A patent/NZ540298A/en not_active IP Right Cessation
- 2003-12-11 JP JP2004558065A patent/JP4490285B2/ja not_active Expired - Fee Related
- 2003-12-11 ES ES03767788T patent/ES2291697T3/es not_active Expired - Lifetime
- 2003-12-11 PL PL377551A patent/PL377551A1/pl not_active Application Discontinuation
- 2003-12-11 PA PA20038592001A patent/PA8592001A1/es unknown
- 2003-12-11 WO PCT/EP2003/014055 patent/WO2004052869A1/en active IP Right Grant
- 2003-12-11 BR BR0317268-6A patent/BR0317268A/pt not_active IP Right Cessation
- 2003-12-11 KR KR1020057010528A patent/KR100743890B1/ko not_active IP Right Cessation
- 2003-12-11 UY UY28121A patent/UY28121A1/es not_active Application Discontinuation
- 2003-12-11 EP EP03767788A patent/EP1572670B1/de not_active Expired - Lifetime
- 2003-12-11 DK DK03767788T patent/DK1572670T3/da active
- 2003-12-11 AU AU2003292229A patent/AU2003292229B2/en not_active Ceased
- 2003-12-11 AR ARP030104577A patent/AR046244A1/es unknown
- 2003-12-11 TW TW092135035A patent/TW200426139A/zh unknown
- 2003-12-11 AT AT03767788T patent/ATE370936T1/de active
- 2003-12-11 PT PT03767788T patent/PT1572670E/pt unknown
- 2003-12-11 CA CA002506441A patent/CA2506441C/en not_active Expired - Fee Related
-
2005
- 2005-05-26 NO NO20052555A patent/NO330139B1/no not_active IP Right Cessation
- 2005-06-07 HR HR20050512A patent/HRP20050512A2/hr not_active Application Discontinuation
-
2006
- 2006-07-06 HK HK06107607.4A patent/HK1085481A1/xx not_active IP Right Cessation
-
2007
- 2007-11-08 CY CY20071101430T patent/CY1106989T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60315886D1 (de) | Substituierte pyrazin- oder pyridin-derivate als glukokinase-aktivatoren | |
DE60315862D1 (de) | Dihydropyridinonderivate als hne-inhibitoren | |
DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
ATE489387T1 (de) | Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren | |
DE602004024420D1 (de) | Chinazolinderivate als antitumormittel | |
ATE387445T1 (de) | Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren | |
ATE369356T1 (de) | Pyridazinon-derivate als cdk2-hemmer | |
DE60317466D1 (de) | Nicotinamid-derivate als pde4-hemmer | |
ATE286036T1 (de) | Heteroaromatische alkynylphenyl-verbindungen als glukokinase-aktivatoren | |
IS7939A (is) | Pýrasólpýridín afleiður | |
ATE478870T1 (de) | Spiroindolinpiperidinderivate | |
ATE460418T1 (de) | Heterocyclocarboxamidderivate | |
ATE450506T1 (de) | Indol-3-schwefelderivate | |
ATE467631T1 (de) | Chinuclidinamidderivate | |
IS7720A (is) | Píperidín-N-oxíð-afleiður | |
IS7872A (is) | Pýrrólópýrimidín afleiður | |
DE50304983D1 (de) | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren | |
ATE438644T1 (de) | Chinazolinderivate | |
DK2248807T3 (da) | N-Phenyl-2-pyrimidinaminderivater | |
ATE297921T1 (de) | Tetrazolylphenyl-acetamide als glukokinaseaktivatoren | |
IS7659A (is) | COX-2 hamlandi pýridín afleiður | |
ATE335729T1 (de) | 3h-chinazoline -4-on derivaten | |
ATE423771T1 (de) | Tetrahydrochinolinderivate | |
ATE353893T1 (de) | Nicotinamid-derivate verwendbar als pde4 inhibitoren | |
ATE394372T1 (de) | G-lactamderivate als prostaglandinagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |